Notice NOT-AR-20-012 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-085 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U54 cooperative agreement applications for Pilot Centers for Precision Disease Modeling. The goal of the Centers is to support collaborative research projects that link current personalized medicine efforts in human subjects with advances in animal genomics and technologies for genetic manipulation and creation of interspecies somatic hybrids. Functionally linking these areas of research will produce programs to enhance the predictive value of preclinical studies based on the use of precision animal models. Centers will create a process by which the research community can nominate unique human genomic variants for a cost effective high-throughput testing in an animal model pipeline. After validation of the expected gene editing, the Centers will establish assays to conduct comprehensive functional and phenotyping analysis to evaluate disease-causing variants. An important mission of the Centers will be the creation and distribution of precision animal model resources and related services to the biomedical community. Therefore, Centers will establish pipelines for preclinical scientific discovery, disease modeling, and development of interventions based on innovative animal models. Because these preclinical pipelines eventually will be an integral part of diagnostics, care and therapeutic treatment of patients, Centers should demonstrate how they intend to achieve this. Even though the Centers will work on a limited number of focused projects, it is expected that the program and pipeline(s) developed by the Center will maintain multifaceted research activities to build core model systems that can be adjusted as required to accommodate a broad spectrum of diseases.

Notice NOT-HL-19-474 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-029 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-19-067 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to conduct large-scale digital clinical trials to test whether digitally-delivered HIV prevention interventions can reduce HIV incidence among U.S. men who have sex with men (MSM) and/or transgender women and men. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV infections, conduct digitally-delivered interventions that promote HIV risk reduction and pre-exposure prophylaxis (PrEP) use, and assess the resulting impact on HIV incidence through mailed HIV test kits or other remote means.

Funding Opportunity RFA-OD-20-002 from the NIH Guide for Grants and Contracts. This FOA encourages grant applications for national Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The important mission of the projects described by this FOA is to provide research resources, which are facilitating the optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIPs trans-NIH mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP's program priorities.

Funding Opportunity PAR-20-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of, pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research.

Funding Opportunity PAR-20-037 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR XX-XXX .

Funding Opportunity PAR-20-084 from the NIH Guide for Grants and Contracts. This Trailblazer Award is an opportunity for New and Early Stage Investigators to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and behavioral sciences. This FOA invites applications from researchers who are at the early stage of their independent careers or those who have not had substantial prior NIH funding. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants are expected to propose research approaches for which there are minimal or no preliminary data. Preliminary Data: Trailblazer applications are meant to be exploratory, novel, and non-incremental. We encourage the submission of high-risk, high-reward projects. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if necessary, some minimal preliminary data is allowed. Minimal preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. Such evidence, if provided, should only be used to bolster and help establish the foundational premise for the Trailblazer application. All preliminary data must be clearly marked and limited to one-half page which may include one figure. Applications including data more than one-half page or more than one figure, will be considered noncompliant with the FOA instructions. Figures containing published data must include citations within the figure legend. Published data that is included in the research plan, biographical sketch or elsewhere in the application must be cited adjacent to each occurrence. Data that is published must be unambiguously identified as such within the application. References and data from widely-available preprints that have a Digital Object Identifier (DOI) are acceptable

Funding Opportunity PA-20-047 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) to develop and validate next-generation single cell analysis technologies and tools. The purpose is to foster the commercialization of innovative single cell analysis technologies for their broad use in biomedical research. The novel single-cell analysis technologies will aid in obtaining a fine-grained and dynamic view of heterogeneous cellular states and intercellular interactions, thereby providing new mechanistic insight into biological processes in health and disease. Applications should define the current state of technologies and tools as a benchmark against which the new approach(es) will be measured. The new approach(es) should provide substantially improved performance in sensitivity, selectivity, spatiotemporal resolution, scalability, multiplexing capability, or non-destructive analysis of molecular or functional measures of single cells. A companion FOA to support STTR Grants is also available see PA-xx-XXX.

Funding Opportunity PA-20-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer Research (STTR) grant applications from small business concerns (SBCs) to develop and validate next-generation single cell analysis technologies and tools. The purpose is to foster the commercialization of innovative single cell analysis technologies for their broad use in biomedical research. The novel single-cell analysis technologies will aid in obtaining a fine-grained and dynamic view of heterogeneous cellular states and intercellular interactions, thereby providing new mechanistic insight into biological processes in health and disease. Applications should define the current state of technologies and tools as a benchmark against which the new approach(es) will be measured. The new approach(es) should provide substantially improved performance in sensitivity, selectivity, spatiotemporal resolution, scalability, multiplexing capability, or non-destructive analysis of molecular or functional measures of single cells.

Notice NOT-NS-20-034 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-033 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-032 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-031 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-030 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-029 from the NIH Guide for Grants and Contracts

Notice NOT-DE-20-005 from the NIH Guide for Grants and Contracts

Notice NOT-DE-20-004 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-012 from the NIH Guide for Grants and Contracts